$BHC

Bausch + Lomb announced phase 3 plans for a dual-action dry eye drop combining lifitegrast and PFHO, after phase 2 results showed a significant reduction in corneal staining at Day 15. The company also reported positive phase 1b data for BL1332, a TRPV1 antagonist eye drop, showing significant pain reduction in a capsaicin challenge model. Both treatments showed acceptable safety profiles. Phase 2 trials for BL1332 are ongoing.

Bausch + Lomb will advance its dry eye treatment to Phase III despite mixed Phase II results. The eye drop, combining lifitegrast and perfluorohexyloctane, missed its primary endpoint but showed statistical significance in a secondary analysis. The company also progresses BL1332 to Phase II after positive pain reduction data in a Phase Ib trial.

Bausch + Lomb will advance its dry eye drug to Phase III trials, focusing on day 15 results after missing day 29 goals. Its pain treatment, BL1332, met Phase Ib goals, reducing pain intensity and duration. The company plans to consult with the FDA.

Toronto’s TSX hit another record, up 97.15 points to 36,759.29, led by telecom and tech. Canadian dollar weakened to 71.78 US cents. Earnings: Stantec beat adjusted profit, CCL topped sales; Pan American Silver missed. Brookfield, TELUS and Rogers reported results. On Wall Street, S&P 500 and Nasdaq reached highs; Cisco fell after results; CPI rose 0.1% m/m.

Canada’s TSX traded near record highs but slipped 68.19 points to 36,593.95 as investors weighed earnings and softer U.S. PPI. The Canadian dollar fell to 71.72 U.S. cents. CCL Industries rose 3.7% after beating sales; Pan American Silver fell 10% after missing profit. Brookfield’s distributable EPS rose, shares little changed.

Bausch Health Companies (BHC) shares rose nearly 40% in July after a Canada regulatory update and a beat-and-raise quarter. Prokedi was added to Quebec’s formulary. In Q2, revenue and adjusted results improved, with adjusted EPS $1.26 vs $1.23 expected, and net income $476M. Bausch raised 2026 revenue to $10.79B-$11.04B and adjusted EBITDA to $4.05B-$4.18B.

Bausch Health Companies Inc. (NYSE:BHC) said CEO Thomas J. Appio was appointed to the board of Bausch + Lomb Corporation (NYSE:BLCO), effective Aug. 5, 2026. Other directors also joined, replacing several who resigned. Bausch Health said it holds about 87% of Bausch + Lomb’s common shares indirectly and supports its strategy.

Bausch Health (NYSE:BHC) reported Q2 2026 results excluding Bausch + Lomb: revenue $1.458B (+16%), adjusted EBITDA $865M (+28%), margin 59.3% (+530 bps), and adjusted operating cash flow $471M. Net debt fell to $13.7B. Full-year 2026 guidance was raised. Headwinds include Aplenzin LOE and CMS rebate impacts.

Bausch Health Companies Inc. (BHC) shares rose about 13.6% after Q2 results beat expectations and 2026 guidance was raised, according to the article. Q2 revenue was about $2.85B vs $2.66B expected, non-GAAP EPS $1.26 vs $1.01, with $670M operating cash flow and $593M free cash flow. The stock moved from the $4s to near $6.9.

Bausch Health (NYSE:BHC) climbed by 28.85 percent on Thursday to end at $6.03 apiece, after announcing a strong second quarter of the year that set the ground for the company’s profit recovery. In an updated report, the pharmaceutical giant said that it swung to a net income of $260 million during the period, marking a 103 percent jump from the $128 million in the same period last year, and helping slash its net loss to $1.171 billion from the $1.431 billion in the previous quarter of the year.